Company profile for Immunic Therapeutics

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Immunic is a biotechnology company developing a clinical pipeline of orally administered, small-molecule therapies for chronic inflammatory and autoimmune diseases. Immunic is developing orally administered, small molecule programs: The company’s lead development program, vidofludimus calcium (IMU-838), is currently in phase 3 and phase 2 clinical trials for the treatment of relapsing and progressive multiple sclerosis, resp...
Immunic is a biotechnology company developing a clinical pipeline of orally administered, small-molecule therapies for chronic inflammatory and autoimmune diseases. Immunic is developing orally administered, small molecule programs: The company’s lead development program, vidofludimus calcium (IMU-838), is currently in phase 3 and phase 2 clinical trials for the treatment of relapsing and progressive multiple sclerosis, respectively, and has shown therapeutic activity in phase 2 clinical trials in patients suffering from relapsing-remitting multiple sclerosis and moderate-to-severe ulcerative colitis.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
1200 Avenue of the Americas Suite 200 New York, NY 10036
Telephone
Telephone
+1 3322559811
youtube
YouTube

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

DDL Conference

Not Confirmed

envelop Contact Supplier

DDL Conference

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.prnewswire.com/news-releases/immunic-to-participate-in-the-8th-annual-evercore-isi-healthcare-conference-in-december-302623149.html

PR NEWSWIRE
26 Nov 2025

https://www.prnewswire.com/news-releases/immunic-inc-reports-third-quarter-2025-financial-results-and-provides-corporate-update-302614351.html

PR NEWSWIRE
13 Nov 2025

https://www.prnewswire.com/news-releases/immunic-to-participate-in-industry-and-investor-conferences-in-november-302593730.html

PR NEWSWIRE
29 Oct 2025

https://www.biospace.com/drug-development/beyond-btk-inhibitors-next-gen-ms-treatments-could-transcend-symptom-management

BIOSPACE
06 Oct 2025

https://www.prnewswire.com/news-releases/immunic-to-participate-in-scientific-and-investor-conferences-in-october-302571937.html

PR NEWSWIRE
01 Oct 2025

https://www.prnewswire.com/news-releases/immunic-presented-key-vidofludimus-calcium-data-at-the-41st-congress-of-ectrims-highlighting-its-potential-in-multiple-sclerosis-302566933.html

PR NEWSWIRE
25 Sep 2025

REF. STANDARDS & IMPURITIES

Upload your portfolio for free, ask us

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty